The medical device company’s stock dropped when the market opened Wednesday after it slashed sales and earnings forecasts once again.

Boston Scientific had another challenging quarter as the fallout from a cyberattack and lingering struggles in two key businesses dragged on the company’s overall performance.

As a result, Boston Scientific slashed its earnings and sales guidance for the third quarter in a row. The company now forecasts full-year revenue growth of 4.25%, compared with a previous range of 5.5% to 6.5%.

The new guidance, released along with third-quarter results, is a far cry from what was projected at the beginning of the year, when Boston Scientific outlined 2026 sales growth expectations of 10.5% to 11.5%.

Boston Scientific also cut its adjusted earnings per share guidance, dropping it to a range of $3.16 to $3.18 from a range of $3.28 to $3.32. In February, the company forecast adjusted EPS growth in a range of $3.43 to $3.49.

The company’s stock price was down by nearly 7% to $42.02 when the market opened Wednesday.

Boston Scientific attributed previous sales guidance cuts to ongoing challenges in its Watchman and electrophysiology businesses, which have traditionally been key growth drivers for the company. Those challenges continued in the third quarter.

CEO Mike Mahoney, on a Wednesday earnings call, said that Watchman sales declined by 6% and electrophysiology by 5%. For comparison, Watchman sales grew by nearly 30% in 2025, and electrophysiology has seen as much as triple-digit growth in past years, fueled by sales of pulsed field ablation devices.

Source link